AMD

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully determined based on disease activity markers.

Panelists discuss how aflibercept’s molecular structure contributes to its clinical efficacy as a standard treatment for retinal vascular diseases.

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.

The biosimilar to reference aflibercept (Eylea, Bayer AG) is indicated to treat retinal diseases including neovascular age-related macular degeneration

Non-invasive, painless laser can reduce risk of vision loss

A large study performed in Canada analyzed data and found that patients are at higher risk of multiple possible complications after cataract surgery.

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells

The biosimilar is indicated to improve and maintain visual acuity for patients with neovascular age-related macular degeneration

Chase Ludwig, MD, speaks about the effect of vitrectomy on the progression of age-related macular degeneration

A novel formulation may prevent blood vessel growth and vascular leakage in the retina

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

The drug is a biosimilar for aflibercept 2 mg (Eylea)

The flagship, light-based technology has received approval for applications in the anterior and posterior segments

The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)

The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen

For decoding biomarkers, a multistage system is just the beginning

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD

At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

I-SCREEN will bring together 12 institutions across Europe, including Queen’s University Belfast

The European Commission is expected to make a decision about the application before the end of June

Research indicates smoking increases risk of AMD, cataracts and glaucoma

Physicians explore how other specialties adopt and integrate remote monitoring

EODM may be an ideal candidate for development of complement gene therapy due to the high-impact genetic variants